Clinicopathologic Features and Treatment Efficacy of Patients with BRAF V600E-mutated Metastatic Colorectal Cancer: a Multi-center Real-world Propensity Score Matching Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Nov 13

PMID 39538135

Authors

Gui-Xia Wei

Yu-Wen Zhou

Chao Dong

Tao Zhang

Peng Cao

Lin Xie

Meng Qiu

Affiliations

Soon will be listed here.

Abstract

Background: Patients with BRAF 600E mutated mCRC are associated with specific clinicopathological features and poor prognosis. The relative efficacy of first-line FOLFOXIRI triplet chemotherapy or doublet chemotherapy combined with bevacizumab in patients with BRAF 600E mutated mCRC remains controversial.

Methods: BRAF V600E-mutated mCRC patients from 3 institutions were included. The clinicopathological characteristics of the enrolled patients were analyzed. Overall survival (OS) of patients was divided into 4 fractions, including 0-25%, 25-50%, 50-75%,75-100% by quartile method. Patients with OS ranging from 0 to 25% were defined as the poor prognosis group, and patients with OS ranging from 75 to 100% were defined as the good prognosis group. A propensity score matching (PSM) analysis was performed to balance the baseline characteristics of patients treated with doublet chemotherapy and triplet chemotherapy combined with bevacizumab. Survival and tumor response of the two regimens were evaluated.

Results: A total of 125 patients with BRAF V600E-mutated mCRC were enrolled. The median OS of BRAF V600E-mutated mCRC was 14.9 months and the median PFS of first-line therapy was 6.1 months. According to the multivariate analysis and the difference in baseline characteristics between the poor prognosis group and the good prognosis group, poor differentiation and liver metastasis were negative independent prognostic factors for OS in patientsx with BRAF V600E-mutated mCRC. Patients treated with first-line triplets had a longer OS than those treated with doublets both before PSM (17.4 months vs. 13.4 months, p = 0.022) and after PSM (17.4 months vs. 10.4 months, p = 0.004). There was no significant benefit between triplet-drug group and doublet-drug group for PFS, ORR and DCR. Subgroup analysis showed that patients in the triplet-drug group had a better prognosis with the following favorable factors: age ≤ 60 years old, PS score of 0-1, liver metastases and multiple organ metastases.

Conclusion: The overall prognosis of BRAF V600E mutant mCRC patients is poor. Poor differentiation and liver metastases were negative independent prognostic factors for OS. First-line triplet-drug therapy was associated with better OS, especially in patients with good physical condition and high tumor burden.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Clarke C, Kopetz E . BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015; 6(6):660-7. PMC: 4671844. DOI: 10.3978/j.issn.2078-6891.2015.077. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007; 370(9596):1453-7. DOI: 10.1016/S0140-6736(07)61602-X. View

Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3):329-359. DOI: 10.6004/jnccn.2021.0012. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Yaeger R, Cercek A, Chou J, Sylvester B, Kemeny N, Hechtman J . BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120(15):2316-24. PMC: 4928876. DOI: 10.1002/cncr.28729. View

Kayhanian H, Goode E, Sclafani F, Ang J, Gerlinger M, Gonzalez de Castro D . Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clin Colorectal Cancer. 2017; 17(1):e69-e76. DOI: 10.1016/j.clcc.2017.10.006. View

Grothey A, Fakih M, Tabernero J . Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021; 32(8):959-967. DOI: 10.1016/j.annonc.2021.03.206. View

Digiacomo N, Bolzacchini E, Veronesi G, Cerutti R, Sahnane N, Pinotti G . Neuroendocrine Differentiation, Microsatellite Instability, and Tumor-infiltrating Lymphocytes in Advanced Colorectal Cancer With BRAF Mutation. Clin Colorectal Cancer. 2019; 18(2):e251-e260. DOI: 10.1016/j.clcc.2018.12.003. View

10.

Afrasanie V, Marinca M, Alexa-Stratulat T, Gafton B, Paduraru M, Adavidoaiei A . KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician. Radiol Oncol. 2019; 53(3):265-274. PMC: 6765160. DOI: 10.2478/raon-2019-0033. View

11.

Guan W, Qiu M, He C, Yang L, Jin Y, Wang Z . Clinicopathologic Features and Prognosis of Mutated Colorectal Cancer Patients. Front Oncol. 2020; 10:563407. PMC: 7720726. DOI: 10.3389/fonc.2020.563407. View

12.

Martinez-Lago N, Fernandez-Montes A, Covela M, M Brozos E, De La Camara J, Mendez Mendez J . Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer. 2021; 21(1):64. PMC: 7807898. DOI: 10.1186/s12885-020-07758-5. View

13.

Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D . Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol. 2020; :JCO2001225. DOI: 10.1200/JCO.20.01225. View

14.

Tabernero J, Ros J, Elez E . The Evolving Treatment Landscape in -Mutated Metastatic Colorectal Cancer. Am Soc Clin Oncol Educ Book. 2022; 42:1-10. DOI: 10.1200/EDBK_349561. View

15.

Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, Lieu C . Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117(20):4623-32. PMC: 4257471. DOI: 10.1002/cncr.26086. View

16.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S . FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13):1306-15. DOI: 10.1016/S1470-2045(15)00122-9. View

17.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T . Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. N Engl J Med. 2019; 381(17):1632-1643. DOI: 10.1056/NEJMoa1908075. View

18.

De La Fouchardiere C, Cohen R, Malka D, Guimbaud R, Bourien H, Lievre A . Characteristics of Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. Oncologist. 2019; 24(12):e1331-e1340. PMC: 6975964. DOI: 10.1634/theoncologist.2018-0914. View

19.

Sinicrope F, Shi Q, Smyrk T, Thibodeau S, Dienstmann R, Guinney J . Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology. 2014; 148(1):88-99. PMC: 4274188. DOI: 10.1053/j.gastro.2014.09.041. View

20.

Seppala T, Bohm J, Friman M, Lahtinen L, Vayrynen V, Liipo T . Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015; 112(12):1966-75. PMC: 4580394. DOI: 10.1038/bjc.2015.160. View